- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Gilead Sciences Inc (GILDm)
Gilead Sciences Inc stock price live, this page displays BCBA GILDm stock exchange data. View the GILDm premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Gilead Sciences Inc real time stock price chart below.
What Is the Gilead Sciences Inc Stock Price Today?
The Gilead Sciences Inc stock price today is 51,650.000.
What Is the Stock Symbol for Gilead Sciences Inc?
The stock symbol for Gilead Sciences Inc is "GILDm."
What Stock Exchange Does Gilead Sciences Inc Trade On?
Gilead Sciences Inc is listed and trades on the Buenos Aires stock exchange.
Is Gilead Sciences Inc a Good Stock to Buy?
Determining whether Gilead Sciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GILDm quote. (ISIN: ARBCOM4601C4)
What Is the Gilead Sciences Inc Stock Price Today?
The Gilead Sciences Inc stock price today is 51,650.000.
What Is the Stock Symbol for Gilead Sciences Inc?
The stock symbol for Gilead Sciences Inc is "GILDm."
What Stock Exchange Does Gilead Sciences Inc Trade On?
Gilead Sciences Inc is listed and trades on the Buenos Aires stock exchange.
Is Gilead Sciences Inc a Good Stock to Buy?
Determining whether Gilead Sciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GILDm quote. (ISIN: ARBCOM4601C4)
51,650.000
+25.000(+0.05%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
51,600.000
52,150.000
52 wk Range
36,225.000
58,100.000
GILDm is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
51,600.00052,150.000
52 wk Range
36,225.00058,100.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.61%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.61%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
GILDm Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 11 consecutive years
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Earnings
Latest Release
May 07, 2026
EPS / Forecast
1.61 / --
Revenue / Forecast
6.96B / --
Compare GILDm to Peers and Sector
Metrics to compare | GILDm | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGILDmPeersSector | |
|---|---|---|---|---|
P/E Ratio | 17.4x | 23.5x | −0.3x | |
PEG Ratio | 0.31 | −0.55 | 0.00 | |
Price/Book | 6.8x | 3.0x | 2.6x | |
Price / LTM Sales | 5.4x | 2.7x | 2.9x | |
Upside (Analyst Target) | - | 31.5% | 57.8% | |
Fair Value Upside | Unlock | 11.4% | 9.5% | Unlock |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Gilead Sciences (GILDm) Stock Price Today?
The Gilead Sciences stock price today is 51,650.000 ARS.
What Stock Exchange Does Gilead Sciences Trade On?
Gilead Sciences is listed and trades on the Buenos Aires Stock Exchange.
What Is the Stock Symbol for Gilead Sciences?
The stock symbol for Gilead Sciences is "GILDm."
Does Gilead Sciences Pay Dividends? What’s The Current Dividend Yield?
The Gilead Sciences dividend yield is 1.61%.
What Is the Gilead Sciences Market Cap?
As of today, Gilead Sciences market cap is 240.260T ARS.
What Is Gilead Sciences's Earnings Per Share (TTM)?
The Gilead Sciences EPS (TTM) is 7.353.
From a Technical Analysis Perspective, Is GILDm a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Gilead Sciences Stock Split?
Gilead Sciences has split 0 times.
How Many Employees Does Gilead Sciences Have?
Gilead Sciences has 17000 employees.
What is the current trading status of Gilead Sciences (GILDm)?
As of Jul 26, 2026, Gilead Sciences (GILDm) is trading at a price of 51,650.000 ARS, with a previous close of 51,625.000 ARS. The stock has fluctuated within a day range of 51,600.000 ARS to 52,150.000 ARS, while its 52-week range spans from 36,225.000 ARS to 58,100.000 ARS.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.